Company Encyclopedia
View More
name
MapLight Therapeutics
MPLT.US
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
1.902 T
MPLT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Market Midday Update: MapLight Therapeutics makes significant progress in new drug trials, stock price surges 11.58%

    MapLight Therapeutics rose 11.58%; Amgen fell 1.37%, with a transaction volume of USD 732 million; Precision BioSciences fell 0.11%, with a transaction volume of USD 702 million; Fortis Pharmaceuticals fell 1.42%, with a transaction volume of USD 425 million; AbbVie fell 0.82%, with a market capitalization of USD 403.7 billion

    Tracking Unusual Activity·
    US
    MPLT
    +3.01%
    Tracking Unusual Activity·
    US
    MPLT
    +3.01%

    MapLight Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MPLT
    +3.01%
    LB filings·
    US
    MPLT
    +3.01%

    MapLight Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MPLT
    +3.01%
    LB filings·
    US
    MPLT
    +3.01%

    MapLight Therapeutics Inc. Q3 net loss rises to USD 29.4 million, up 55 percent

    MapLight Therapeutics Inc. reported a Q3 2025 net loss of USD 29.4 million, up 55%. Research and development expenses increased by 61% to USD 27.1 million, while general and administrative expenses were USD 4.4 million. Total operating expenses for Q3 reached USD 31.5 million. The company raised USD 296.5 million from its IPO and private placement, ensuring funding through 2027.

    Reuters·
    US
    MPLT
    +3.01%
    Reuters·
    US
    MPLT
    +3.01%

    Maplight Therapeutics, Inc.'s (NASDAQ:MPLT) Quiet Period To End on December 8th

    Maplight Therapeutics' quiet period ends on December 8th, following its IPO on October 27th, where 14,750,000 shares were issued at $17.00 each, totaling $250,750,000. Post-quiet period, brokerages are expected to initiate research coverage. Analysts have given the stock a Buy rating, with an average price target of $31.00. The stock opened at $13.63, with a 12-month range of $12.24 to $20.86. Maplight Therapeutics focuses on CNS disorders and has received various ratings from analysts.

    Market Beat·
    US
    MPLT
    +3.01%
    Market Beat·
    US
    MPLT
    +3.01%
    © 2025 Longbridge｜Disclaimer